Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

L Ferrè, F Clarelli, G Sferruzza, MA Rocca, E Mascia, M Radaelli, Francesca Sangalli, G Dalla Costa, L Moiola, M Aboulwafa, F Martinelli Boneschi, G Comi, M Filippi, V Martinelli, F Esposito

Research output: Contribution to journalArticle

Abstract

Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs. Aims: To investigate whether baseline 25[OH] D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY). Patients and methods: We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans. Results: We found no linear correlation between baseline 25[OH] D levels and annualized relapse rate (ARR) or time to first relapse. However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH] D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05). Conclusions: In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient. © 2018 Springer-Verlag Italia S.r.l., part of Springer Nature
Original languageEnglish
Pages (from-to)1467-1470
Number of pages4
JournalNeurological Sciences
Volume39
Issue number8
DOIs
Publication statusPublished - 2018

Fingerprint

Vitamin D
Multiple Sclerosis
Recurrence
Fingolimod Hydrochloride
Pharmaceutical Preparations
Magnetic Resonance Imaging
Safety
Therapeutics
Serum

Cite this

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. / Ferrè, L; Clarelli, F; Sferruzza, G; Rocca, MA; Mascia, E; Radaelli, M; Sangalli, Francesca; Dalla Costa, G; Moiola, L; Aboulwafa, M; Martinelli Boneschi, F; Comi, G; Filippi, M; Martinelli, V; Esposito, F.

In: Neurological Sciences, Vol. 39, No. 8, 2018, p. 1467-1470.

Research output: Contribution to journalArticle

Ferrè, L, Clarelli, F, Sferruzza, G, Rocca, MA, Mascia, E, Radaelli, M, Sangalli, F, Dalla Costa, G, Moiola, L, Aboulwafa, M, Martinelli Boneschi, F, Comi, G, Filippi, M, Martinelli, V & Esposito, F 2018, 'Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod', Neurological Sciences, vol. 39, no. 8, pp. 1467-1470. https://doi.org/10.1007/s10072-018-3440-0
Ferrè, L ; Clarelli, F ; Sferruzza, G ; Rocca, MA ; Mascia, E ; Radaelli, M ; Sangalli, Francesca ; Dalla Costa, G ; Moiola, L ; Aboulwafa, M ; Martinelli Boneschi, F ; Comi, G ; Filippi, M ; Martinelli, V ; Esposito, F. / Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. In: Neurological Sciences. 2018 ; Vol. 39, No. 8. pp. 1467-1470.
@article{3dff6d25fac742caa6c466288b7416e8,
title = "Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod",
abstract = "Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs. Aims: To investigate whether baseline 25[OH] D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY). Patients and methods: We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans. Results: We found no linear correlation between baseline 25[OH] D levels and annualized relapse rate (ARR) or time to first relapse. However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH] D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05). Conclusions: In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient. {\circledC} 2018 Springer-Verlag Italia S.r.l., part of Springer Nature",
author = "L Ferr{\`e} and F Clarelli and G Sferruzza and MA Rocca and E Mascia and M Radaelli and Francesca Sangalli and {Dalla Costa}, G and L Moiola and M Aboulwafa and {Martinelli Boneschi}, F and G Comi and M Filippi and V Martinelli and F Esposito",
year = "2018",
doi = "10.1007/s10072-018-3440-0",
language = "English",
volume = "39",
pages = "1467--1470",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "8",

}

TY - JOUR

T1 - Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

AU - Ferrè, L

AU - Clarelli, F

AU - Sferruzza, G

AU - Rocca, MA

AU - Mascia, E

AU - Radaelli, M

AU - Sangalli, Francesca

AU - Dalla Costa, G

AU - Moiola, L

AU - Aboulwafa, M

AU - Martinelli Boneschi, F

AU - Comi, G

AU - Filippi, M

AU - Martinelli, V

AU - Esposito, F

PY - 2018

Y1 - 2018

N2 - Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs. Aims: To investigate whether baseline 25[OH] D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY). Patients and methods: We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans. Results: We found no linear correlation between baseline 25[OH] D levels and annualized relapse rate (ARR) or time to first relapse. However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH] D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05). Conclusions: In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient. © 2018 Springer-Verlag Italia S.r.l., part of Springer Nature

AB - Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs. Aims: To investigate whether baseline 25[OH] D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY). Patients and methods: We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans. Results: We found no linear correlation between baseline 25[OH] D levels and annualized relapse rate (ARR) or time to first relapse. However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH] D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05). Conclusions: In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient. © 2018 Springer-Verlag Italia S.r.l., part of Springer Nature

U2 - 10.1007/s10072-018-3440-0

DO - 10.1007/s10072-018-3440-0

M3 - Article

VL - 39

SP - 1467

EP - 1470

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 8

ER -